MY153976A - Lh liquid formulations - Google Patents

Lh liquid formulations

Info

Publication number
MY153976A
MY153976A MYPI2010001950A MYPI20101950A MY153976A MY 153976 A MY153976 A MY 153976A MY PI2010001950 A MYPI2010001950 A MY PI2010001950A MY PI20101950 A MYPI20101950 A MY PI20101950A MY 153976 A MY153976 A MY 153976A
Authority
MY
Malaysia
Prior art keywords
liquid formulations
relates
pharmaceutical formulations
liquid pharmaceutical
luteinizing hormone
Prior art date
Application number
MYPI2010001950A
Other languages
English (en)
Inventor
Agostinetto Rita
Samaritani Fabrizio
Del Rio Alessandra
Richard Joel
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of MY153976A publication Critical patent/MY153976A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MYPI2010001950A 2007-11-01 2008-10-29 Lh liquid formulations MY153976A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07119832 2007-11-01
US448107P 2007-11-28 2007-11-28

Publications (1)

Publication Number Publication Date
MY153976A true MY153976A (en) 2015-04-30

Family

ID=39167502

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2010001950A MY153976A (en) 2007-11-01 2008-10-29 Lh liquid formulations

Country Status (25)

Country Link
US (1) US8664369B2 (https=)
EP (1) EP2219607B1 (https=)
JP (1) JP5551601B2 (https=)
KR (1) KR101513181B1 (https=)
CN (1) CN101842083B (https=)
AU (1) AU2008320844B2 (https=)
BR (1) BRPI0818324B8 (https=)
CA (1) CA2700662C (https=)
CY (1) CY1113121T1 (https=)
DK (1) DK2219607T3 (https=)
EA (1) EA019432B1 (https=)
EC (1) ECSP10010224A (https=)
ES (1) ES2393233T3 (https=)
HR (1) HRP20120660T1 (https=)
IL (1) IL205105A (https=)
MX (1) MX2010004639A (https=)
MY (1) MY153976A (https=)
NZ (1) NZ583991A (https=)
PL (1) PL2219607T3 (https=)
PT (1) PT2219607E (https=)
RS (1) RS52566B (https=)
SI (1) SI2219607T1 (https=)
UA (1) UA101484C2 (https=)
WO (1) WO2009056569A1 (https=)
ZA (1) ZA201001907B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102007143B (zh) 2008-01-09 2015-08-26 塞诺菲-安万特德国有限公司 具有超延迟时效特征的新型胰岛素衍生物
CN102256618A (zh) 2008-10-17 2011-11-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
JP2011001273A (ja) * 2009-06-16 2011-01-06 Eci Inc ｅＭＩＰを有効成分とする水溶性製剤
PL2451437T3 (pl) * 2009-07-06 2017-05-31 Sanofi-Aventis Deutschland Gmbh Wodne preparaty insuliny zawierające metioninę
NZ599847A (en) 2009-11-13 2013-09-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
TR201809460T4 (tr) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
RU2553375C2 (ru) * 2010-02-12 2015-06-10 Интас Биофармасьютикалс Лимитед Жидкий состав фолликулостимулирующего гормона
WO2012028172A1 (en) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN102293756A (zh) * 2011-08-24 2011-12-28 蚌埠丰原涂山制药有限公司 一种尿促性素冻干粉针剂及其制备方法
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
JP2016505601A (ja) * 2012-12-26 2016-02-25 ウォックハート リミテッド 医薬組成物
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
CN105960249B (zh) 2014-01-09 2021-03-16 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
JP6723921B2 (ja) 2014-01-09 2020-07-15 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
US9895423B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
PE20171622A1 (es) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
GB201603280D0 (en) * 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE64738B1 (en) * 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
US5681302A (en) * 1994-06-14 1997-10-28 Minnesota Mining And Manufacturing Company Elastic sheet-like composite
WO1996029095A1 (en) * 1995-03-21 1996-09-26 Applied Research Systems Ars Holding N.V. Hcg liquid formulations
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
CN1309567A (zh) * 1998-07-23 2001-08-22 伊莱利利公司 Fsh和fsh变体制剂,产品和方法
DE602004019761D1 (de) * 2003-01-08 2009-04-16 Novartis Vaccines & Diagnostic Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
US7387998B2 (en) 2003-03-28 2008-06-17 New York University STQ peptides
CA2518903C (en) * 2003-04-02 2013-02-05 Ares Trading S.A. Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant

Also Published As

Publication number Publication date
EA019432B1 (ru) 2014-03-31
HRP20120660T1 (hr) 2012-09-30
AU2008320844A1 (en) 2009-05-07
ZA201001907B (en) 2011-05-25
JP5551601B2 (ja) 2014-07-16
KR101513181B1 (ko) 2015-04-21
BRPI0818324B1 (pt) 2019-12-24
KR20100088147A (ko) 2010-08-06
CA2700662C (en) 2015-10-13
ECSP10010224A (es) 2010-07-30
CA2700662A1 (en) 2009-05-07
EP2219607B1 (en) 2012-08-15
RS52566B (sr) 2013-04-30
ES2393233T3 (es) 2012-12-19
IL205105A0 (en) 2010-11-30
UA101484C2 (en) 2013-04-10
MX2010004639A (es) 2010-08-04
SI2219607T1 (sl) 2012-09-28
US20100261649A1 (en) 2010-10-14
NZ583991A (en) 2012-02-24
US8664369B2 (en) 2014-03-04
WO2009056569A1 (en) 2009-05-07
BRPI0818324A2 (pt) 2017-05-16
HK1145443A1 (en) 2011-04-21
PT2219607E (pt) 2012-08-31
EP2219607A1 (en) 2010-08-25
IL205105A (en) 2015-04-30
JP2011502968A (ja) 2011-01-27
CY1113121T1 (el) 2016-04-13
DK2219607T3 (da) 2013-06-17
AU2008320844B2 (en) 2013-08-29
PL2219607T3 (pl) 2012-12-31
CN101842083B (zh) 2012-11-14
CN101842083A (zh) 2010-09-22
EA201070549A1 (ru) 2010-10-29
WO2009056569A9 (en) 2010-01-21
BRPI0818324B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
MY153976A (en) Lh liquid formulations
EP2381773A4 (en) COMPOSITIONS FOR THE ADMINISTRATION OF MEDICINAL PRODUCTS
JOP20200039A1 (ar) مُستحضر صيدلي يشتمل على hcg مأشوب
EA031157B9 (ru) Вводимая перорально кортикостероидная композиция
WO2013188792A3 (en) Neuroactive steroids, compositions, and uses thereof
EP2152195A4 (en) PEPTIDATE MEDICINAL FOR ORAL LEVY
CL2008000690A1 (es) Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras.
UA99337C2 (ru) Жидкая лекарственная форма фсг
WO2011141685A3 (fr) Compositions nasales a visee systemique a base de cocoyl proline ou d'au moins un de ses constituants
WO2011062437A3 (ko) 고나도트로핀 방출 호르몬 수용체 길항제, 이의 제조방법 및 이를 함유하는 약제학적 조성물
IN2012DN02139A (https=)
EP2035488A4 (en) MICELLES FOR DRUG DELIVERY
EP2394648A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
DK2482881T3 (da) Mekanisme til indretning til indlevering af lægemiddel
BR112015030387A2 (pt) compostos de pirazol como moduladores de fshr e usos dos mesmos
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
WO2007103867A3 (en) Tablet formulations and processes
TN2009000510A1 (en) Extended release formulation of nevirapine
ZA200807348B (en) Dosage aerosols for the administration of pharmaceutical preparations
WO2015125152A3 (en) Pharmaceutical compositions of asenapine
AU2009298305A8 (en) Pharmaceutical composition utilising combinations of variants of the gonadotropin-liberating hormone (GnRH) as immunogen
WO2008034909A3 (en) Second line treatment of metastatic hormone refractory prostate cancer using satraplatin
PL2114367T3 (pl) Formulacje olopatadyny do miejscowego podawania donosowo
PL2253326T3 (pl) Kompozycja farmaceutyczna do podawania przeznosowego
MX2009002985A (es) Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (tsh).